SCHEMBL31419752

SCHEMBL31419752

Cn1ccc2c(CO)cncc21

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NFATC1 O95644 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
TDO2 P48775 1/20 0.35
MAPT P10636 3/20 0.34
GPR84 Q9NQS5 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
SCN9A Q15858 1/20 0.34
ATR Q13535 1/20 0.33
NQO2 P16083 1/20 0.33
PIK3CB P42338 1/20 0.32
DHFR P00374 1/20 0.31
HTR2A P28223 1/20 0.31
PDE5A O76074 1/20 0.31
TRPV1 Q8NER1 1/20 0.30
GRM4 Q14833 1/20 0.30
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29115222 1.00 NFATC1 (0.37) NFATC1GSK3BDYRK1ATDO2MAPT
SCHEMBL21803773 0.77 HTR6 (0.40) MAPTGPR84KDM4EALDH1A1RXFP1
SCHEMBL23937723 0.76 NFATC1 (0.36) NFATC1GSK3BDYRK1AMAPTKDM4E
SCHEMBL1288089 0.74 KDM4E (0.48) MAPTGPR84KDM4EALDH1A1RXFP1
SCHEMBL12670777 0.73 NFATC1 (0.37) NFATC1GSK3BDYRK1AMAPTKDM4E
SCHEMBL20656340 0.72 NFATC1 (0.36) NFATC1GSK3BDYRK1AMAPTKDM4E
SCHEMBL21893814 0.72 DHFR (0.44) NFATC1GSK3BDYRK1AMAPTKDM4E
SCHEMBL30702049 0.72 NFATC1 (0.36) NFATC1GSK3BDYRK1AMAPTKDM4E
SCHEMBL8114127 0.71 KDM4E (0.34) MAPTGPR84KDM4EALDH1A1RXFP1
SCHEMBL12432935 0.70 GPR84 (0.33) MAPTGPR84KDM4EALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS FGFR3, FGFR1, FGFR2 NFATC1 3977/4885GSK3B 225/4885DYRK1A 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.